Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Parkinson Disease, Autonomic Nervous System Diseases, Pure Autonomic Failure
Interventions
6-[18F]Fluorodopamine, 6-[18F]Fluorodopa, 13N-Ammonia
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 70 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Parkinson's Disease
Interventions
capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)
Drug
Lead sponsor
Novartis
Industry
Eligibility
30 Years to 80 Years
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
17
States / cities
Phoenix, Arizona • La Jolla, California • Reseda, California + 13 more
Conditions
Parkinson Disease
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
21 Years and older · Female only
Enrollment
30 participants
Timeline
2023 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Parkinson Disease
Interventions
Ropinirole
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years and older
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
28
States / cities
Birmingham, Alabama • Northridge, California • San Francisco, California + 24 more
Conditions
Parkinson's Disease
Interventions
Parcopa
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
40 Years and older
Timeline
2005
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Glioblastoma, Malignant Glioma
Interventions
Computed Tomography, Fluorodopa F 18, Magnetic Resonance Imaging, Positron Emission Tomography, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Temozolomide
Procedure · Other · Radiation + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Completed No phase listed Observational Accepts healthy volunteers

Complex Eye Movements in Parkinson's Disease and Related Movement Disorders

NCT04925622
Conditions
Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, Corticobasal Degeneration, Parkinsonian Disorders, Essential Tremor, Vascular Parkinsonism, Multiple System Atrophy, Parkinson Variant, Parkinsonian Syndrome, Huntington Disease
Interventions
Complex eye movement exam
Diagnostic Test
Lead sponsor
Saccadous, Inc.
Other
Eligibility
30 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Completed Phase 2 Interventional Results available

Cognitive Remediation for Cocaine Dependence

NCT01393457
Conditions
Cocaine Dependence
Interventions
levodopa/carbidopa, Ropinirole 2 mg/d, Placebo, Ropinirole 4 mg/d
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 55 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Houston, Texas
Conditions
Parkinson's Disease (PD)
Interventions
ABBV-951
Drug
Lead sponsor
AbbVie
Industry
Eligibility
45 Years to 85 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
Glendale, California • Orlando, Florida • Grayslake, Illinois + 4 more
Conditions
Parkinson Disease
Interventions
Vibrotactile coordinated reset
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Stanford, California
Terminated Phase 2 Interventional Accepts healthy volunteers

Carbidopa-Levodopa in Dry AMD With Geographic Atrophy

NCT03451500
Conditions
Age Related Macular Degeneration
Interventions
carbidopa-levodopa
Drug
Lead sponsor
Snyder, Robert W., M.D., Ph.D., P.C.
Individual
Eligibility
50 Years to 85 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tucson, Arizona
Completed Phase 2 Interventional Results available

Dose Ranging Study of Carbidopa-levodopa

NCT03023059
Conditions
Age-related Macular Degeneration
Interventions
Carbidopa-Levodopa, 25 Mg-100 Mg Oral Tablet
Drug
Lead sponsor
Snyder, Robert W., M.D., Ph.D., P.C.
Individual
Eligibility
50 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Parkinson Disease
Interventions
RO7486967, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Englewood, Colorado + 6 more
Conditions
Parkinson's Disease With End of Dose Wearing Off
Interventions
Carbidopa/levodopa/entacapone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
30 Years to 85 Years
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
41
States / cities
Phoenix, Arizona • Fullerton, California • Irvine, California + 38 more
Conditions
Parkinson's Disease
Interventions
PF-06649751
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
16
States / cities
Fountain Valley, California • Long Beach, California • Englewood, Colorado + 10 more
Conditions
Parkinson Disease
Interventions
HB-adMSCs, Placebo
Biological · Other
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Sugar Land, Texas
Conditions
Parkinson's Disease
Interventions
ND0612 (Levodopa/Carbidopa solution), ND0612 (Levodopa/Carbidopa solution) + morning oral IR-LD/CD
Drug
Lead sponsor
NeuroDerm Ltd.
Industry
Eligibility
30 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Chicago, Illinois • Farmington Hills, Michigan • Cincinnati, Ohio
Conditions
Parkinson's Disease, Parkinson Disease, Dyskinesias
Interventions
ropinirole controlled-release (REQUIP CR) for RLS
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 70 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
69
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 61 more
Conditions
Parkinson's Disease
Interventions
Istradefylline ( KW-6002)
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
30 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Princeton, New Jersey
Conditions
Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
Interventions
Dipraglurant, Placebo
Drug
Lead sponsor
Addex Pharma S.A.
Industry
Eligibility
30 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
41
States / cities
Phoenix, Arizona • Fresno, California • Irvine, California + 38 more
Completed Phase 3 Interventional Results available

Efficacy of Isradipine in Early Parkinson Disease

NCT02168842
Conditions
Parkinson Disease
Interventions
Isradipine, Placebo (for Isradipine)
Drug
Lead sponsor
University of Rochester
Other
Eligibility
30 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
47
States / cities
Birmingham, Alabama • Sun City, Arizona • Fountain Valley, California + 40 more
Recruiting Not applicable Interventional Accepts healthy volunteers

Action Regulation Behavioral

NCT06489483
Conditions
Parkinson Disease
Interventions
Action Regulation Movement Task
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Parkinson's Disease (PD)
Interventions
ABBV-951
Drug
Lead sponsor
AbbVie
Industry
Eligibility
30 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
15
States / cities
Birmingham, Alabama • Sun City, Arizona • Aurora, Colorado + 12 more
Conditions
Parkinson's Disease
Interventions
Tozadenant (SYN115) 60 mg BID, Placebo, Levodopa (L-dopa), Tozadenant (SYN115) 120 mg BID, Tozadenant (SYN115) 180 mg BID, Tozadenant (SYN115) 240 mg BID
Drug
Lead sponsor
Biotie Therapies Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
40
States / cities
Birmingham, Alabama • La Jolla, California • Loma Linda, California + 37 more